All In Biotech

Drug Trial Radar · NCT02422940

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.

An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets. for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits .

Last checked: Nov 20, 2026Latest source record: Jan 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 294 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

294

Actual

Start

Apr 2015

Primary completion

Jan 2017

Study completion Jan 2017

Sponsor

Lead sponsor
Acorda TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.

Conditions

  • Post-ischemic Stroke

Interventions

  • dalfampridine-ER 7.5 mgDrug

  • dalfampridine-ER 10 mgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Primary Objective Was to Evaluate Serious and Non-serious Adverse Events for Study Participants as a Measure of Safety and Tolerability of Dalfampridine ER (Extended Release) for at Least 12-months.Time frame: up to 12 months

Locations

66 sites in 2 countries. Site status is shown where the registry gives one.

  • Acorda Site #117

    Gilbert, Arizona

  • Acorda Site #109

    Berkeley, California

  • Acorda Site #170

    Carlsbad, California

  • Acorda Site #138

    Long Beach, California

  • Acorda Site #105

    Newport Beach, California

  • Acorda Site #142

    Pasadena, California

  • Acorda Site #153

    Sacramento, California

  • Acorda Site #151

    San Diego, California

  • Acorda Site #163

    San Diego, California

  • Acorda Site #124

    Colorado Springs, Colorado

  • Acorda Site #110

    Danbury, Connecticut

  • Acorda Site #149

    Fairfield, Connecticut

  • Acorda Site #130

    Stamford, Connecticut

  • Acorda Site #115

    Atlantis, Florida

  • Acorda Site #119

    Deerfield Beach, Florida

  • Acorda Site #147

    Gainesville, Florida

  • Acorda Site #128

    Hialeah, Florida

  • Acorda Site #184

    Jacksonville, Florida

  • Acorda Site #103

    Miami, Florida

  • Acorda Site #133

    Miami, Florida

  • Acorda Site #161

    Naples, Florida

  • Acorda Site #106

    Tampa, Florida

  • Acorda Site #181

    Honolulu, Hawaii

  • Acorda Site #171

    Chicago, Illinois

  • Acorda Site #148

    Avon, Indiana

  • Acorda Site #188

    Fort Wayne, Indiana

  • Acorda Site #156

    Franklin, Indiana

  • Acorda Site #146

    Lexington, Kentucky

  • Acorda Site #150

    New Orleans, Louisiana

  • Acorda Site #175

    Fulton, Maryland

  • Acorda Site #136

    Boston, Massachusetts

  • Acorda Site #121

    Boston, Massachusetts

  • Acorda Site #123

    East Lansing, Michigan

  • Acorda Site #164

    Farmington Hills, Michigan

  • Acorda Site #159

    Grand Rapids, Michigan

  • Acorda Site #101

    Kansas City, Missouri

  • Acorda Site #111

    Great Falls, Montana

  • Acorda Site #140

    Reno, Nevada

  • Acorda Site #131

    New Brunswick, New Jersey

  • Acorda Site #177

    Stratford, New Jersey

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.